Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Rufinamide

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 80210 refers to a laboratory test specifically designed for the monitoring of therapeutic levels of rufinamide, which is an antiepileptic medication. Rufinamide is primarily utilized in the treatment of seizures associated with Lennox-Gastaut syndrome, a severe form of epilepsy that affects both children and adults, as well as for managing focal seizures in adolescents and adults. The purpose of therapeutic drug monitoring (TDM) is to ensure that the drug levels remain within a therapeutic range, which is crucial for maximizing efficacy while minimizing the risk of toxicity. This monitoring is particularly important for patients who may be taking other medications that could interact with rufinamide or those undergoing hemodialysis, as these factors can significantly influence drug metabolism and clearance. The elimination half-life of rufinamide ranges from 6 to 10 hours, indicating the time it takes for half of the drug to be eliminated from the body, which occurs through hepatic metabolism. Effective management of seizures is associated with mean plasma concentration trough levels of rufinamide between 5.0 and 30 mcg/mL. This range is broad due to individual variability in drug absorption and clearance, as well as the potential impact of co-administered medications. Levels exceeding 30 mcg/mL have been associated with toxicity, which can manifest through various adverse effects, including headache, dizziness, fatigue, nausea, and drowsiness. To accurately assess rufinamide levels, a blood specimen is typically collected just before the next scheduled dose or at least 12 hours after the last dose of a sustained-release formulation. The collected sample must be processed promptly; it is centrifuged to separate the serum from blood cells within two hours of collection and then stored in a plastic vial for analysis. The concentration levels of rufinamide are determined using advanced techniques such as quantitative solid phase extraction-tandem mass spectrometry or quantitative liquid chromatography-tandem mass spectrometry, ensuring precise measurement of the drug in the bloodstream.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The laboratory test associated with CPT® Code 80210 is indicated for the following conditions:

  • Monitoring Therapeutic Levels: The test is performed to monitor the therapeutic levels of rufinamide in patients undergoing treatment for seizures.
  • Lennox-Gastaut Syndrome: It is specifically indicated for patients with Lennox-Gastaut syndrome, a severe form of epilepsy that presents with multiple types of seizures.
  • Focal Seizures: The test is also applicable for adults and adolescents experiencing focal seizures, allowing for effective management of their condition.
  • Assessing Compliance: Therapeutic drug monitoring helps assess patient compliance with the prescribed medication regimen.
  • Avoiding Toxicity: The test aids in avoiding toxicity by ensuring that rufinamide levels remain within a safe and effective range.
  • Adjusting Dosage: It is crucial for adjusting the dosage in patients who may be taking other medications that interact with rufinamide or those on hemodialysis.

2. Procedure

The procedure for conducting the laboratory test associated with CPT® Code 80210 involves several critical steps to ensure accurate measurement of rufinamide levels:

  • Step 1: Blood Specimen Collection - A blood specimen is drawn from the patient just prior to the next scheduled dose of rufinamide or at least 12 hours after the last dose of a sustained-release formulation. This timing is essential to obtain a trough level that accurately reflects the drug concentration in the bloodstream.
  • Step 2: Sample Processing - After collection, the blood sample must be processed promptly. The specimen is centrifuged within two hours to separate the serum from the blood cells. This step is crucial to prevent any interference from cellular components that could affect the test results.
  • Step 3: Sample Storage - The separated serum is then placed in a plastic vial for storage and transport to the laboratory for analysis. Proper storage conditions must be maintained to ensure the integrity of the sample until testing is performed.
  • Step 4: Analytical Methodology - The concentration levels of rufinamide in the serum are determined using advanced analytical techniques, specifically quantitative solid phase extraction-tandem mass spectrometry or quantitative liquid chromatography-tandem mass spectrometry. These methods provide precise and reliable measurements of the drug concentration, which are essential for effective therapeutic monitoring.

3. Post-Procedure

Post-procedure care following the blood specimen collection for CPT® Code 80210 is generally minimal, as the primary focus is on the analysis of the serum sample. However, it is important to monitor the patient for any immediate adverse reactions to the blood draw, such as bruising or discomfort at the puncture site. Once the results of the rufinamide level are obtained, healthcare providers will review the findings to assess whether the drug concentration is within the therapeutic range. If the levels are found to be outside the recommended range, adjustments to the dosage may be necessary. Additionally, ongoing monitoring may be required for patients on rufinamide, especially those who are also taking other medications or undergoing hemodialysis, to ensure continued efficacy and safety of the treatment regimen.

Short Descr DRUG ASSAY RUFINAMIDE
Medium Descr DRUG ASSAY RUFINAMIDE
Long Descr Rufinamide
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) none
MUE 1
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
Date
Action
Notes
2021-01-01 Added Code added.
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"